We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

73 hedge funds and large institutions have $639M invested in Apellis Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

725% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 4

313% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 8

70% more capital invested

Capital invested by funds: $375M → $639M (+$264M)

52% more funds holding

Funds holding: 48 → 73 (+25)

18.13% more ownership

Funds ownership: 33.83% → 51.96% (+18%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
73
Holders Change
+25
Holders Change %
+52.08%
% of All Funds
1.67%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
33
Increased
33
Reduced
4
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HIM
Hillhouse Investment Management
Cayman Islands
+$66.6M
2
BlackRock
BlackRock
New York
+$38.9M
3
State Street
State Street
Massachusetts
+$23.8M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.1M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$22M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$23.4M
2
ACA
Avoro Capital Advisors
New York
-$7.45M
3
SI
Sofinnova Investments
California
-$6.8M
4
Norges Bank
Norges Bank
Norway
-$1.66M
5
CCP
Clough Capital Partners
Massachusetts
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACP
26
Acuta Capital Partners
California
$3.7M +$3.86M +168,000 New
Prudential Financial
27
Prudential Financial
New Jersey
$2.97M +$3.1M +134,900 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.8M +$2.12M +92,280 +265%
TCIM
29
TIAA CREF Investment Management
New York
$2.49M +$2.15M +93,746 +486%
SFM
30
Sphera Funds Management
Israel
$2.44M +$2.55M +110,803 New
AllianceBernstein
31
AllianceBernstein
Tennessee
$2.25M +$2.35M +102,443 New
EP
32
Eversept Partners
New York
$2.16M +$2.26M +98,395 New
AA
33
ALPS Advisors
Colorado
$1.79M +$1.87M +81,182 New
Morgan Stanley
34
Morgan Stanley
New York
$1.75M +$1.36M +59,125 +288%
Deutsche Bank
35
Deutsche Bank
Germany
$1.54M +$1.28M +55,538 +386%
TA
36
Teachers Advisors
New York
$1.52M +$1.19M +51,696 +299%
Balyasny Asset Management
37
Balyasny Asset Management
Illinois
$1.44M +$1.5M +65,428 New
Goldman Sachs
38
Goldman Sachs
New York
$1.42M +$1.49M +64,670 New
JP Morgan Chase
39
JP Morgan Chase
New York
$1.23M +$1.23M +53,514 +2,403%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$1.22M +$886K +38,544 +230%
Russell Investments Group
41
Russell Investments Group
United Kingdom
$1.1M – – –
California Public Employees Retirement System
42
California Public Employees Retirement System
California
$1.03M +$1.08M +46,916 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$884K +$669K +29,100 +262%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$810K +$845K +36,800 New
VEA
45
Virtus ETF Advisers
New York
$797K +$832K +36,223 New
ASP
46
Adams Street Partners
Illinois
$796K +$832K +36,194 New
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$747K +$566K +24,645 +265%
VMI
48
VHCP Management II
New York
$654K +$683K +29,710 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$645K +$673K +29,300 New
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$606K +$412K +17,912 +187%
1
2
3 4

APLS Hedge Fund Activity: Q2 2018 in Review

73 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2018, worth a combined $639M — up 70% from $375M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new APLS positions and 8 closed out — a net gain of 25 holders — while 33 added to existing stakes and 4 trimmed.

The largest buyer was Hillhouse Investment Management, adding an estimated $66.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $23.4M sold.

  • 73 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2018, up from 48 in Q1 2018.
  • Funds reported $639M of Apellis Pharmaceuticals stock for Q2 2018, up 70% quarter-over-quarter.
  • 33 funds opened new Apellis Pharmaceuticals positions in Q2 2018 and 8 closed out, a net change of +25 holders.
  • The largest Apellis Pharmaceuticals buyer in Q2 2018 was Hillhouse Investment Management, an estimated $66.6M added.
  • The largest Apellis Pharmaceuticals seller in Q2 2018 was EcoR1 Capital, an estimated $23.4M sold.

Based on aggregated 13F filings for Q2 2018.